Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience.
Maham
N
N
University Health Network, University of Toronto, Toronto, Ontario, Canada.
Cardella
C
C
Cattran
D
D
Fenton
S
S
O'Grady
C
C
Hamill
J
J
Smith
R
R
Cole
E
E
D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
D007166:Immunosuppressive Agents; D007518:Isoantibodies; D016572:Cyclosporine